The Great Indian GLP-1 Boom: Weight-Loss Drugs, Counterfeits, and India's Looming Metabolic Reckoning

This journal describes The rapid growth of GLP-1 medications in India is transforming the landscape of diabetes and obesity treatment. This article explores the growing Indian semaglutide market, focusing on Ozempic, the impact of patent expiry, the emergence of affordable generic alternatives, and the changing pharmaceutical market. It also examines the growing concerns surrounding counterfeit medicines, unregulated sales, unsupervised use, potential adverse effects, and regulatory challenges. By analysing market developments, clinical evidence, and reported incidents, this article highlights the urgent need for stronger pharmacovigilance, quality control, responsible prescribing, and effective regulatory oversight. Ultimately, it explores a critical question: Can affordable access to weight-loss medicines translate into better public health without compromising patient safety? A narrative policy analysis of India's evolving GLP-1 market and its implications for pharmaceutical regulation and public health.